Clinical Trial Update: Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of osimertinib and anlotinib for advanced non-small cell lung cancer with EGFR mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor | Phase 1, Phase 2 | Status: COMPLETED